---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002781"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:24:16.628053+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025

## Summary
- Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.
- Q1 2025 net income $43.1M (basic EPS $5.12); diluted net loss per share ($2.11) due to warrant fair value change.
- Phase 2 B-SUPREME study of ALG-000184 in chronic HBV expected to begin mid-2025; interim data 2026, topline 2027.
- ALG-055009 (THR-β agonist) Phase 2a HERALD showed placebo-adjusted median liver fat reduction up to 46.2%; up to 70% subjects achieved ≥30% reduction.
- ALG-097558 pan-coronavirus inhibitor has 3 clinical trials ongoing; NIAID study Q2 2025. Company seeking external funding for further development.

## SEC filing metadata
- accession: 0001171843-25-002781
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/0001171843-25-002781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/f8k_050525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002781
- JSON: https://secwatch.observer/filing/0001171843-25-002781.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.